A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: A randomized phase II study to evaluate toxicity and dose intensity

Ken Hirao, Hirofumi Kawamoto, Ichiro Sakakihara, Yasuhiro Noma, Naoki Yamamoto, Ryo Harada, Koichiro Tsutsumi, Masakuni Fujii, Hironari Kato, Naoko Kurihara, Osamu Mizuno, Tsuneyoshi Ogawa, Etsuji Ishida, Kazuhide Yamamoto

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Fingerprint Dive into the research topics of 'A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: A randomized phase II study to evaluate toxicity and dose intensity'. Together they form a unique fingerprint.

Medicine & Life Sciences